18.02.2022 - Presentation to highlight oral difelikefalin Phase 3 pruritus programsSTAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) - Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to .
Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
What happened
Shares of
Cara Therapeutics (NASDAQ:CARA) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis.
So what
With the biotech stock falling so heavily today, you d think that all the results from the phase 2 trial were really bad. That wasn t entirely the case, though.